Johnson & Johnson Announces Positive Results from OMNY-AF Study

Hedge funds see JNJ as one of the best medical research stocks to buy

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

Johnson & Johnson (NYSE:JNJ) announced positive 12-month pilot-phase data from the OMNY-AF study, evaluating an investigational platform for the treatment of symptomatic paroxysmal atrial fibrillation. The initial results showed 100% acute procedural success with no adverse events, and 90% of patients achieved primary effectiveness at 12 months. Additionally, RBC Capital and BofA have raised their price targets on JNJ, citing the company's strong financial position and enhanced business fundamentals.

Why it matters

The positive results from the OMNY-AF study and the increased price targets from analysts suggest that Johnson & Johnson's medical research and development efforts are paying off, making it an attractive investment option for hedge funds and other investors in the healthcare sector.

The details

The OMNY-AF study evaluated Johnson & Johnson's investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation. The 12-month pilot-phase data showed that investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases were performed with zero fluoroscopy, and 90% of patients achieved primary effectiveness at 12 months. Additionally, RBC Capital raised its price target on JNJ to $255 from $240, maintaining an Outperform rating, and BofA lifted its price target to $227 from $221, maintaining a Neutral rating.

  • On February 6, Johnson & Johnson announced the 12-month pilot-phase data from the OMNY-AF study at the 31st Annual AF Symposium in Boston.
  • On February 3, RBC Capital raised its price target on Johnson & Johnson to $255 from $240.
  • On January 30, BofA lifted its price target on Johnson & Johnson to $227 from $221.

The players

Johnson & Johnson

A multinational corporation that develops, manufactures, and sells products in the healthcare field, including pharmaceuticals, medical devices, and consumer goods.

RBC Capital

A global investment bank and financial services company that provides research, advisory, and capital markets services.

BofA

Bank of America, a multinational investment bank and financial services company.

Got photos? Submit your photos here. ›

What they’re saying

“It is unlikely for the key implications of the Daubert ruling to be undone. However, the cases may drag on for years as Johnson & Johnson (NYSE:JNJ) litigates this case-by-case and year-by-year, maintaining a strong financial position by enhancing business fundamentals to help mitigate risks.”

— RBC Capital, Analyst (RBC Capital)

“The increased price target points towards a higher blended P/E multiple, which in turn assumes a raised MedTech multiple on a higher pharma multiple and higher organic growth, given a defensive premium.”

— BofA, Analyst (Bank of America)

What’s next

The judge in the Daubert ruling case will decide on whether to allow the key implications of the ruling to be undone, which could have a significant impact on Johnson & Johnson's legal battles.

The takeaway

Johnson & Johnson's positive results from the OMNY-AF study and the increased price targets from analysts suggest that the company's medical research and development efforts are paying off, making it an attractive investment option for hedge funds and other investors in the healthcare sector. However, the company's ongoing legal battles related to the Daubert ruling may continue to be a source of uncertainty for investors.